Hanmi Pharm Co Ltd (128940)
KOSDAQ · Korea · prices in KRW · close of 19 Oct 2026
Key indicators
| Last close | KRW 389,500.00 |
|---|---|
| 52-week range | 302,000.00 – 644,642.99 |
| Return, 1 month / 3 months | −17.8% / +9.3% |
| Return, 1 year / 3 years | +6.5% / +41.5% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 76.9% |
| Worst drawdown (1 year) | -50.1% |
| Average daily value traded | 62,328.82M KRW |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hanmi Pharmaceutical is a Korean pharmaceutical company that develops and makes prescription medicines. Its products include treatments for high blood pressure, diabetes, digestive disorders and other chronic conditions, along with specialty medicines and health-related products. The company serves patients and healthcare providers mainly in Korea, and it also works with partners abroad on developing and licensing new drugs. Hanmi Pharmaceutical is based in Seoul, Korea, where it carries out research, manufacturing and commercial operations.
The shares are listed on the KOSDAQ in Korea under the code 128940, and the price on this page is in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hanmi Pharm Co Ltd (128940) trades on the KOSDAQ in Korea. It last closed at KRW 389,500.00 on 19 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 422 of 1,830 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.5% and over the last three months it rose 9.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on KOSDAQ
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -16.7% | ||
| From 52-week high | -37.6% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 9.3% | ||
| 6-month return | -22.1% | ||
| 12-month return, skipping the last month | 29.6% | ||
| Risk (lower is better) | 52 · Fair | Typical risk for this exchange. | |
| Volatility (1 year) | 76.9% | ||
| Worst drawdown (1 year) | -50.1% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 62,328.82M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −17.9% |
|---|---|
| 1 month | −17.8% |
| 3 months | +9.3% |
| 6 months | −22.1% |
| 1 year | +6.5% |
| 3 years | +41.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 461,730.00 / 467,376.82 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 30,444.51 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Mar 2026 | KRW 2,000.0000 |
| 27 Dec 2024 | KRW 1,000.0000 |
| 27 Jun 2024 | KRW 250.0000 |
| 27 Dec 2023 | KRW 510.0000 |
| 28 Dec 2022 | KRW 510.0000 |
| 29 Dec 2021 | KRW 510.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on KOSDAQ; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.